Zealand Pharma (ZEAL) Plummets 25% on Survodutide Tolerability Concerns

TLDR

Table of Contents

Zealand Pharma shares declined approximately 25% following Phase III survodutide data revealing significant patient dropout numbers
Between 23% and 25% of trial participants discontinued survodutide treatment due to digestive system side effects, compared to 5.4% placebo discontinuation
The drug demonstrated substantial weight reduction reaching 16.6% versus 3.2% in the placebo group, despite tolerability challenges
Goldman Sachs analysts highlighted that poor tolerability may constrain the medication’s market penetration in obesity treatment
Wolfe Research maintained its positive “outperform” stance with a DKK750 target price, suggesting more than 129% potential gains from pre-decline prices

Zealand Pharma (ZEAL) experienced a dramatic market value erosion of approximately 25% on Monday after publishing Phase III clinical trial results for survodutide, its obesity medication developed in partnership with Boehringer Ingelheim, which demonstrated that nearly 25% of participants abandoned treatment due to adverse reactions.

Zealand Pharma A/S, ZEAL

Shares plummeted roughly 25% during Copenhagen market hours. Novo Nordisk, Zealand’s bigger competitor in the weight management sector, also experienced a modest 2% decline the same day.

The SYNCHRONIZE-1 clinical study tracked 725 adults living with obesity or carrying excess weight without Type 2 diabetes over a 76-week period. Weight reduction achieved up to 16.6% on the efficacy estimand compared to 3.2% among placebo recipients — representing impressive efficacy metrics.

However, the patient tolerance profile painted a more concerning picture.

Patient withdrawal rates reached 23.7% and 24.8% among those receiving 3.6mg and 6mg dosages respectively, dramatically exceeding the 5.4% placebo withdrawal rate. The primary driver: digestive system complications, which accounted for 17.8% and 20.2% of discontinuations at each dosage level versus only 2.9% among placebo users.

Goldman Sachs analysts addressed these figures explicitly, indicating that suboptimal tolerability will probably restrict survodutide’s market adoption in obesity therapeutics.

Wolfe Research identified an additional confounding factor. Approximately 16.5% of placebo group participants utilized a prohibited GLP-1 receptor agonist throughout the study period, artificially elevating placebo group weight loss and diminishing the observable treatment advantage.

The research firm also highlighted how the study’s inflexible protocol design contributed to elevated discontinuation figures, referencing investigator commentary regarding the challenges of conducting strictly controlled versus adaptable trials.

Impressive Efficacy Results Provide Some Reassurance

Notwithstanding the adverse event issues, the effectiveness data contained genuinely positive elements.

A body composition analysis substudy utilizing MRI imaging across 75 participants demonstrated that survodutide 6mg generated a 34% relative decrease in visceral adipose tissue versus 11.8% for placebo. Hepatic fat declined 63.1% compared to 24.5% among placebo recipients, and lean tissue represented no more than 10.8% of total body mass alteration at the maximum dosage.

The companion SYNCHRONIZE-MASLD study, conducted over 48 weeks with 218 adults experiencing obesity and metabolic-associated liver disease, similarly delivered positive outcomes. As many as 84.2% of survodutide-treated patients achieved at least a 30% relative hepatic fat reduction, versus 24.3% receiving placebo. Body weight decreased 12.2% compared to 1% among placebo subjects.

What Remains Ahead for Zealand

Zealand Pharma stands to receive high single-digit to low double-digit percentage royalties on worldwide survodutide revenue, alongside €315 million in potential remaining milestone compensation. Boehringer Ingelheim maintains complete responsibility for clinical development and market commercialization.

Wolfe Research preserved its “outperform” recommendation with a DKK750 target valuation — representing approximately 130% upside potential from the pre-decline closing price.

Separately, Novo Nordisk announced that prescription volumes for its Wegovy oral weight-loss medication have surpassed three million since the product’s market introduction in early January.

✨ Limited Time Offer